DEF 14A: Xilio Seeks Reverse Stock Split to Maintain Nasdaq Listing

Xilio Therapeutics, Inc. will hold a special meeting on February 23, 2026, for stockholders to vote on a reverse stock split to meet Nasdaq's minimum bid price requirement.

Summary

• Xilio Therapeutics, Inc. is holding a special meeting on February 23, 2026, to vote on an amendment to its Restated Certificate of Incorporation to effect a reverse stock split.
• The proposed reverse stock split ratio will be within a range of not less than 1-for-2 and not greater than 1-for-30, with the exact ratio and timing to be determined by the board of directors.
• The primary purpose of the reverse stock split is to increase the per share market price of common stock to maintain listing on the Nasdaq Capital Market and avoid delisting due to the minimum bid price requirement.
• Xilio received a written notification from Nasdaq on April 4, 2025, indicating non-compliance with the $1.00 minimum bid price requirement.
• The company's common stock was transferred to the Nasdaq Capital Market on October 6, 2025, granting an additional 180-calendar day period, until March 30, 2026, to regain compliance.
• As of January 13, 2026, the closing bid price for Xilio's common stock on the Nasdaq Capital Market was $0.6558 per share.
• The board of directors unanimously recommends that stockholders vote 'FOR' the adoption and approval of the reverse stock split and 'FOR' the approval of an adjournment of the special meeting if necessary to solicit further proxies.
• As of January 2, 2026, there were 67,540,930 shares of common stock issued and outstanding.
• The reverse split will decrease the number of outstanding shares but will not change the total number of authorized shares (600,000,000 common stock and 5,000,000 preferred stock).
• Stockholders who would otherwise hold fractional shares as a result of the reverse split will receive a cash payment in lieu of such fractional shares, calculated based on the closing price on the trading day preceding the effective date.

Sentiment

Score: 3

Explanation: The filing addresses a critical issue (potential delisting) with a proposed solution (reverse stock split). While proactive, the need for a reverse split itself indicates significant stock price weakness and underlying challenges. The outcome of the split is uncertain, and there are acknowledged risks, leading to a cautious, slightly negative sentiment.

Positives

• The proposed reverse stock split is a proactive measure by the board to address the Nasdaq minimum bid price deficiency and avoid potential delisting.
• Maintaining the Nasdaq listing is expected to improve the marketability and liquidity of the common stock, potentially attracting long-term and institutional investors.
• A higher stock price may help generate investor interest and make the company more attractive for attracting and retaining employees.
• The board's discretion to determine the exact ratio (within 1-for-2 to 1-for-30) and timing provides flexibility to implement the split in a manner deemed most advantageous.

Negatives

• The company's common stock has fallen below Nasdaq's $1.00 minimum bid price requirement, leading to a delisting notice on April 4, 2025.
• The current closing price of $0.6558 per share (as of January 13, 2026) is significantly below the required minimum, necessitating this action.
• Reverse stock splits often carry a negative perception among investors, analysts, and other stock market participants.
• There is no assurance that the reverse stock split will result in a sustained increase in the per share price or prevent future declines.

Risks

• The reverse stock split may not result in an increase in the per share price of common stock following the split or in the future, and the price may not remain above the $1.00 minimum bid price required by Nasdaq.
• The market price per share of common stock after the reverse split may not rise in proportion to the reduction in the number of shares outstanding.
• The liquidity of common stock may be negatively impacted by the reduced number of shares outstanding after the reverse split, especially if the per-share market price does not increase.
• The reverse split may result in some stockholders owning 'odd lots' (less than 100 shares), which can be more difficult and costly to sell.
• The resulting per-share price may still fail to attract institutional investors or satisfy their investing guidelines, thus not improving trading liquidity or marketability.
• An increase in the relative amount of authorized but unissued shares of common stock could be construed as having an anti-takeover effect, potentially diluting stock ownership.

Future Outlook

The company aims to increase its per share market price through a reverse stock split to maintain its Nasdaq listing. This action is intended to improve marketability, attract institutional investors, and aid in future capital raising and employee retention. However, the company acknowledges that there is no assurance the reverse split will achieve these desired outcomes or prevent future delisting.

Management Comments

• "We believe enabling the board of directors to fix the specific ratio will provide us with the flexibility to implement the Reverse Split in a manner designed to maximize the anticipated benefits to us and our stockholders."
• "Our board of directors determined that any potential negative factors are outweighed by the potential benefits of the Reverse Split."
• "We believe that effecting the Reverse Split will help us avoid delisting from Nasdaq and any resulting consequences."
• "Accordingly, we believe that the Reverse Split is our best proactive option for complying with the minimum bid price requirement for continued listing on the Nasdaq Capital Market."

Industry Context

The proposed reverse stock split by Xilio Therapeutics reflects a common challenge faced by small-cap biotechnology companies whose stock prices fall below exchange minimums. Maintaining a Nasdaq listing is crucial for visibility, liquidity, and attracting institutional investment, which are vital for companies in the capital-intensive biotech sector to fund research, development, and potential commercialization efforts. Delisting can severely hamper a company's ability to raise necessary capital and compete for talent, potentially isolating it from mainstream financial markets.

Corporate Governance

Stakeholder Impact

• Shareholders: Will own fewer shares but maintain the same proportional ownership (subject to cash payment for fractional shares). The goal is to increase per-share price and marketability, but there's a risk of further price decline and reduced liquidity.
• Employees: A higher stock price may help attract and retain employees, particularly through equity compensation.
• Investors (Institutional/Brokerage Firms): A higher stock price may make the common stock more attractive for investment by firms with policies against low-priced stocks, potentially increasing institutional interest.
• Nasdaq: The reverse split is intended to bring the company into compliance with Nasdaq's minimum bid price requirement, thereby avoiding delisting and preserving the company's access to a major exchange.

Next Steps

• Stockholders will vote on the reverse stock split and adjournment proposals at the special meeting on February 23, 2026.
• If the reverse stock split is approved, the board of directors will determine the exact ratio (within the 1-for-2 to 1-for-30 range) and timing of its implementation.
• The company plans to announce preliminary voting results at the special meeting and report final results in a Current Report on Form 8-K within four business days following the meeting.
• If implemented, the Reverse Split Charter Amendment will be filed with the Secretary of State of Delaware.
• The company must regain compliance with Nasdaq's $1.00 minimum bid price requirement by March 30, 2026.

Key Dates

Recommendation

The proposed reverse stock split is a critical defensive measure to maintain Xilio Therapeutics' Nasdaq listing, which is essential for its market visibility, liquidity, and future capital-raising capabilities. While this action addresses an immediate threat, the underlying stock price weakness necessitating the split indicates ongoing challenges. Reverse splits often carry negative market sentiment and do not guarantee a sustained price recovery. Investors should hold to observe the effectiveness of the split in stabilizing the stock price and await further disclosures on the company's operational and financial performance before making more aggressive investment decisions. A 'buy' is premature given the current situation, and a 'sell' would be too reactive given the proactive steps to preserve exchange listing.

Keywords

Reverse Stock Split, Nasdaq Listing, Delisting Risk, Xilio Therapeutics, XLO, Proxy Statement, Corporate Governance, Shareholder Meeting, Biotechnology, Stock Price Compliance